GFI1 influences the prognosis of AML, CML and MPN patients in a dose-dependent manner, and reduced levels of GFI1 accelerated disease development in murine models of human leukemia (Kok et al., 2013; Hönes et al., 2016; Volpe et al., 2017; Vadnais et al., 2018). This evidence concerns the gene GFI1 and myeloproliferative disorder.